MGTX:NASDAQMeiraGTx Holdings plc Analysis

MeiraGTx (MGTX) is trading at $9.49, marginally below its 20‑day SMA of $9.52 but comfortably above the 200‑day SMA of $8.23, indicating a lingering bullish bias. The MACD histogram is negative and the signal line is bearish, while the RSI sits near the neutral 50 mark, suggesting mixed short‑term momentum. Volume is on an increasing trend, yet the 30‑day volatility exceeds 85% and beta approaches 2.0, flagging pronounced price swings. The DCF‑derived fair value of roughly $6.15 is well below the current price, implying the stock is currently overvalued on a discounted cash‑flow basis.
Fundamentally, the company reports steep revenue contraction of ‑85% and deep operating losses, but it maintains a positive operating cash flow and a sizable free cash flow buffer of over $45 M. With a cash balance of $71 M offset by $87 M of debt, the balance sheet is modestly leveraged. The pipeline of gene‑therapy programs and collaborations with Johnson & Johnson and Hologen provide a strong growth narrative, reflected in a “strong buy” consensus from eight analysts and target prices near $26‑$28. Recent upbeat media headlines tout MGTX as a top growth stock under $10, adding short‑term sentiment fuel, while upcoming earnings are expected to be negative, reinforcing near‑term uncertainty.